Maca Energy Randomized Trial: What the Evidence Says

Quick Answer

Maca Energy Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 preclinical study, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Under normal conditions, it is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (Keap1), which targets it for degradation. [Cipriano Giovanni Luca (2026); evidence level 4]
• The following subsections provide a detailed analysis of the molecular profiles and clinical evidence for these three primary bioactives. [Cipriano Giovanni Luca (2026); evidence level 4]
• Thresholds of MP associated with the development of VILI have been established, suggesting that maintaining MP below these thresholds can be safer. [Burša Filip (2025); evidence level 4]
• At the beginning of the study, all attending physicians were instructed that MP values above 17 J/min should be prevented as such values have been reported to be associated with adverse outcomes. [Burša Filip (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For maca energy randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Cipriano Giovanni Luca (2026). Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy. DOI: 10.3390/ijms27083607. PMCID: PMC13116414. PMID: 42074246. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13116414/
• Burša Filip (2025). Protective mechanical ventilation controlled by the real-time mechanical power measurement. DOI: 10.1007/s10877-025-01369-w. PMCID: PMC12963077. PMID: 41075121. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12963077/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.